Acute myeloid leukemia · 6 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
7+3d and Midostaurin Variant #01 | FLT3 | R 50 467 | 21d | — | 74.7 mo | — | — | 1 |
7+3i Variant #01 | FLT3 | R 17 152 | 7d | — | 12.9 mo | — | — | 2 |
7+3i and Quizartinib Variant #01 Partial | FLT3 | R 17 152 | 21d | — | 31.9 mo | — | — | 1 |
DA 3+10 Variant #01 | FLT3 | R 12 698 | 10d | — | — | — | — | 2 |
7+3d and Quizartinib Variant #01 Partial | FLT3 | R 11 746 | 21d | — | 31.9 mo | — | — | 1 |
7+3d Variant #01 | FLT3 | R 6 129 | — | — | 15.1 mo | — | — | 11 |
6 of 6 regimens shown